+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Scar Treatment Market Report 2021-2031

22 February 2021

Visiongain has published a new report on Scar Treatment Market Report 2021-2031: Forecasts By Product (Topical Products, Laser Products, Injectables, and Others), By Scar Type (Atrophic Scars, Hypertrophic And Keloid Scars, Contracture Scars, Stretch Marks, and Others), By Patient Demographics (Adults, Geriatric, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Scar Treatment market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Scar Treatment market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Scar Treatment Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Scar Treatment market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Availability of Reimbursement in Developing Nations
Governments and private insurance players have increased reimbursement approvals for skin related disease due to increase in the number of atrophic scars, hypertrophic and keloid scars, contracture scars, stretch marks cases. Demand for topical products, laser products, injectables, and others is increasing very rapidly in developing nations due to availability of reimbursement for scar treatment in developing nations. Due to this reason the factor is working as a driver for the market.

Increasing Geriatric Population around the World
An increasing in geriatric population is suffering from aging scars as elderly people are more prone to aging scars. All regions are facing a huge increase in the number of geriatric populations. For instance: According to the United Nations, Department of Economic and Social Affairs, the Population Division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Rapid increase in the number of the geriatric population around the globe is increasing the demand for scar treatment around the world. Due to which increasing geriatric population around the world is working as a driver for the scar treatment market.

Market Opportunities

Increasing focus on Healthcare Infrastructure
Governments from all over the world are increasing their focus on healthcare infrastructure and advanced healthcare facilities and are taking necessary steps to create or modify healthcare infrastructure. Healthcare infrastructure in developing nations are undergoing tumultuous changes from the last few years and each change is only for a better healthcare delivery, and to incorporate all the sections of the population. Increasing focus on healthcare infrastructure is expected to increase public spending which is expected to create new opportunities for the scar treatment market, Moreover, the public private spending will also aid the market growth during the forecast period. Due to this reason the factor is creating various opportunities for the scar treatment market.

Competitive Landscape

Top companies (Valeant Pharmaceuticals International, Inc., Smith & Nephew, and Merz North America, Inc.) constitute more than XX% share of the global Scar Treatment market. Other companies profiled in the report include: LUMENIS, Enaltus LLC, Sonoma Pharmaceuticals, Inc., Mölnlycke Health Care, Cynosure, Inc., CCA Industries, Inc., Scar Heal Inc., NewMedical Technology, Suneva Medical Inc., Pacific World Corporation, Perrigo Company plc, and XIO Group (Lumenis) Some of the key developments are listed below:

● In 2017, Sonoma Pharmaceuticals, Inc. received regulatory approval for Epicyn Scar Hydrogel (hypochlorous acid) United Arab Emirates Ministry of Health & Prevention. Hydrogel is specifically designed for the management of scars. The launch will help the company to expand Scar Treatment and widen revenue generation from a market focused product portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2024-2034

The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.

20 February 2024


Visiongain Publishes Biobanking Market Report 2024-2034

The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.

19 February 2024


Visiongain Publishes Dermatological Drugs Market Report 2024-2034

The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.

13 February 2024


Visiongain Publishes Allergic Rhinitis Drugs Market Report 2024-2034

The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.

12 February 2024